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Brief introduction to the complement system
Nowadays there are three generally acknowledged complement pathways: classical, alternative and lectin, which differ in initiating mechanisms and molecules participating in the early stages of cascade activation. Additionally, there are two more mechanisms distinguished recently, i.e. direct processing of the C3 molecule by proteases, and the properdin-driven pathway 1 . The formation of the C3 and C5 convertase enzyme complexes are key events in complement activation, and also the stage at which all pathways converge. These convertases activate C3 and C5, causing the release of chemoattractants (C5a and C3a), opsonization of surfaces with C3b, and cell lysis due to assembly of the membrane-attack complex (MAC) 1 built on the platform of cell-associated C5b molecule. This system may be efficient enough to remove all the complement-activating cells, unless membrane bound or soluble complement inhibitors interfere with the process.
Tumor cells activate the complement system
Transformation from normal to malignant phenotype is often reflected in cell membrane composition due to accompanying metabolic changes. There are reports showing that altered glycosylation patterns 2 , changed proportions of phospholipids 3 , lipid peroxidation 4 or exposure of novel tumor epitopes 5 distinguish cancer cells from their normal counterparts and make them visible to the immune system, including complement. Indeed, complement activation via the classical, lectin and alternative pathways by tumors of different origin was described already 30 years ago 6, 7, 8, 9, 10 .
However, spontaneous complement activation by tumor cells has usually little or no therapeutic importance, since tumor cells often overexpress complement inhibitors and tumor-specific antibodies are present at low titer or have low affinity 11 . Nevertheless, the fact that tumor cells usually overexpress one or more membrane-bound complement inhibitors 12 13 , produce substantial amounts of soluble complement inhibitors 14, 15 or develop strategies to counterattack complement activation 11, 16, 17 suggest that controlling complement activation is pivotal for tumorigenesis. More to this end, an oncogenic virus Kaposi's sacroma herpesvirus (KSHV/HHV8), which is an etiologic factor responsible for Kaposi's sarcoma and certain lymphoproliferative malignancies, encodes its own complement inhibitor -KCP 18, 19 . On the other hand, there are reports showing that tumor cells may benefit from triggering complement activation, by mechanisms such as the C5a-dependent recruitment of myeloid-derived suppressor cells 20 or induction of proangiogenic factors 21 . Also, under hypoxia some tumor cells seem to purposely give up their mechanisms of protection from complement 22 , which is in sharp contrast to endothelial cells, which increase the expression of complement inhibitors under hypoxia 23 . Interest in complement as a significant effector mechanism of the immune response has been greatly renewed since mAb therapeutics were introduced, and the vulnerability of tumor cells to CDC was classified as one of the predictors of efficacy of mAb-based cancer therapy 24, 25 . Also, a promising outlook for the experimental application of bispecific antibodies interacting with both tumor antigens and complement inhibitors on tumor cell surfaces has also turned attention to complement in the context of cancer 26 .
CD20 and CD20 mAb
CD20 is a suitable target for immunotherapy due to its presence in high numbers on most (but not all) individual tumor B cells, limited internalization and long persistence on the surface after being bound by antibodies 27, 28 . Also, it is expressed at the majority of B cell developmental stages 29 . So far there is no ligand for CD20 identified and CD20 knockout mice appear to have no discernible B cell defects 30, 31 but display changes in calcium signaling upon activation and reduced IgM expression on the surface 30 .
Nonetheless, the role of CD20 in proliferation, activation and survival of B cell has been suggested based on the effects of specific antibodies 29, 32 as well as the role in proper generation of B cell responses based on a case report of a patient lacking surface CD20 expression 33 . Binding of CD20 by mAb can result in different effector mechanisms such as CDC, which stems from direct lysis due to MAC formation, antibody dependent cellular cytotoxicity (ADCC) employing immune cells bearing Fc-receptors, or direct induction of apoptosis. The outcome depends partially, besides the class of antibody used, on the epitope recognized by a given antibody and its proximity to the cell membrane 34 , but also on the ability to relocalize and cluster CD20 molecules into lipid rafts 27, 35 . Generally, anti-CD20 antibodies are classified into two types: type I, which clusters CD20 into lipid microdomains and potently activate complement but do not directly induce apoptosis, and type II, which does not relocate CD20 and are therefore weak CDC activators, but are strong inducers of apoptosis (or caspase-independent cell death, as described for tositumomab 36 and reactive oxygen species -dependent cell death described for obinutuzumab 37 ). Importantly, both classes retain the ability to activate ADCC 29 . The possible downstream effects of anti-CD20 antibodies bound to the surface of B cells are described in Fig. 1 . An important question emerging at this point is which of the given mechanisms is the most important for the in vivo therapeutic effect.
Rituximab is a class I antibody and since approval as a treatment for patients with CD20+ B cell lymphomas, it has contributed to a 50% reduction of mortality of patients with diffuse large B cell lymphomas, which is the biggest success in lymphoma treatment in the last half century 38 . This, along with the beneficial effects of rituximab in low-grade NHL and CLL (if combined with chemotherapy), is why there is much interest in elucidating the main effector mechanisms of anti-CD20 reagents, as well as other anticancer mAbs, due to the potentials for increasing eficacy by improvement of effector mechanisms through antibody selection or engineering,
Are CDC and ADCC direct competitors?
In spite of the fact that CDC and ADCC lead to the same end point, i.e. cell lysis and death, they do not always seem to work in a synergistic manner. In fact CDC and ADCC may compete with each other, most probably due to steric hindrance caused by early complement component deposition on the surface of target cells 39 . Addition of serum but not heat -inactivated serum to rituximab-coated cells inhibited activation of NK cells and this effect was dependent on the presence of C1q and C3 in serum, but not C5. The same phenomenon was found when authors replaced serum with transudative pleural fluid or nonmalignant ascites in order to establish a model for extravascular fluids, where most B cell lymphoma cells appear to reside (e.g. in lymph nodes) 40 . The occurrence of CDC and ADCC depends on a certain threshold of CD20 molecules present on the surface of target cells. However, CDC requires a much higher expression of specific antigen and the correlation between cell-surface CD20 and CDC is described by a sigmoidal curve 41 . Interestingly, maximal ADCC (analyzed at a 1:10 target / effector cell ratio) was achieved at an absolute number of CD20 molecules lower than that necessary for saturation of CDC (measured using 50% serum). The authors concluded that ADCC and CDC act in a cooperative manner since cells resistant to one killing mechanism were sensitive to the other and vice versa. However, there are several potential reasons for the resistance of individual cells to killing, and the observed results do not exclude the previous hypothesis of direct competition between CDC and ADCC upon rituximab treatment. Recently this hypothesis was further confirmed by a study using immortalized NK cells as effectors for ADCC 42 . Such a model, which allows reproducible cytotoxic activity omits the problem of variation of ADCC efficiency between different patients and even the same patient examined at different time points.
However, the hypothesis of antagonism between CDC and ADCC was not tested for CD20 antibodies other than rituximab, and as related to steric hindrance, may not hold for different monoclonal reagents such as ofatumumab, which bind to alternative epitopes on CD20.
Concluding ¨per analogiam¨ is not possible
Currently there are more than ten agents targeting CD20, which are clinically approved or in clinical testing (originally reviewed in 43, 44, 29, 35, 45 and listed here in Table   1 , which is compiled from these references, updated and modified). Accordantly, there are a number of published studies aiming to identify the molecular basis of the exerted clinical effects. However, the main translational problem is that in spite of noncontradictory results (e.g. these obtained for ofatumumab in CLL 46, 47, 48 ) these antibodies recognize different epitopes of CD20, localized at various distances from the cell membrane. This variable appears to be of major importance for efficacy, as described in terms of T cell mediated lysis 49 or in terms of complement activation and CDC 50,34,51 .
Moreover, different antibodies may induce differing mobility and further segregation of Ab-Ag complexes into membrane rafts, with potential importance for complement activation, as shown for the panel of mAbs recognizing CD20 antigen 52 . Ofatumumab serves as good example of a similar immunotherapeutic, whose mechanism of action should not be translated directly to e.g. rituximab. Although both are class I anti-CD20 antibodies, ofatumumab binds an epitope located more proximal to the cell surface, which is more conducive to triggering CDC and significantly lowers the threshold of surface-exposed CD20 molecules necessary to allow cell lysis 34, 47, 48, 53 . Recently, ofatumumab was shown to exert clinical responses in rituximab -refractory NHL patients patients 54 as well as in fludarabine / alemtuzumab -refratory CLL 55 . Similarly, some of the clinically tested anti-CD20 mAbs were engineered to enhance ADCC 56,57 but these modifications and their effects could not distinguish either CDC or ADCC as a crucial effector mechanism for the parental compound. An important lesson comes from veltuzumab, a humanized anti-CD20 IgG1 mAb containing the same complementarity determining regions (CDRs) as rituximab, but with a single aa substitution in the CDR3 region (Asp101 to Asn), and with a Fc domain derived from another immunotherapeutic, epratuzumab 58 . Although epratuzumab does not exhibit any CDC activity, veltuzumab triggers CDC even more efficiently than rituximab when tested on Daudi cells 58, 59 .
Therefore, results and conclusions obtained for different anti-CD20 antibodies cannot be directly extrapolated to each other, as overall efficacy is determined by multiple factors of the antibody structure and the experimental setting. Another problem in assessing antibody suitability is associated with differences in human and murine complement, since many studies are performed in mouse models. In addition to the presence of unique inhibitors (Crry 60 ) or altered functionality of other common inhibitors (C4b-binding protein, C4BP 61 ), serum from most laboratory mouse strains shows considerably weaker lytic activity comparing to other species including humans, as reported by Ong and Mattes 62 . Further, it was demonstrated that the classical complement pathway in mice exists mainly at an initiation level because of critical changes in C4 structure, which disable further classical C5 convertase activity 63 .
Are the data from animal models really contradictory?
Knowing the above limitations regarding interspecies and inter-antibody extrapolation, one can consider the seemingly contradictory results obtained from different animal studies and ex vivo assays. Controversies over the most important effector mechanism mainly concern rituximab, whereas for other CD20 antibodies existing results give unanimous conclusions. For example, the in vivo therapeutic effect of tositumomab is not affected by decomplementation by cobra venom factor (CVF) 64 .
Ofatumumab appeared more effective in controlling lymphoma xenograft growth than rituximab and this feature correlated with superior CDC capabilities in vitro 65 . However, one mouse model showed that ADCC may play an important role in ofatumumab's therapeutic effect 66 . Nonetheless, this model did not judge the relative contributions of CDC and ADCC. Depletion of NK cells and neutrophils totally abrogates veltuzumabmediated prolonged survival of SCID mice injected with Raji cells and thus underlines the importance of ADCC for this antibody 58 . Returning to controversies, a 38C13 murine lymphoma model and MS11G6 anti-lymphoma mAbs were used to mimic the human model of leukemia treatment by rituximab. In such a system, depletion of C3 from mouse serum prolonged survival and increased NK-dependent ADCC compared to mAb alone 40 . Uchida et al. studied depletion of B cells in mice upon injection of different mouse anti-mouse CD20 antibodies and concluded that elimination was dependent on FcR receptors and was performed mainly by monocytes/macrophages and was not facilitated by complement, as demonstrated in C3 and C4 deficient animals 67 . In contrast to these studies, Di Gaetano et al. showed, using the mouse lymphoma cell line EL4 stably expressing human CD20 (EL4-CD20), that rituximab's therapeutic effect is not dependent on NK cells and neutrophils, and is also possible in athymic mice. In addition, C1qdeficient mice were not protected from tumor burden by rituximab, showing that complement plays a role in rituximab's effect 68 . Having differing studies, where first one seems to dismiss the role of complement in therapeutic effects whereas the latter underlines the importance of complement, one may ask which of these two models properly reflects the action of this mAb in B cell malignancies. To make the question even more complex, another study performed on the same EL4-CD20 model concluded that ADCC and CDC have different impacts on rituximab's therapeutic effect depending on the local tumor burden 69 . Authors inoculated wild type or FcR receptor deficient mouse intraperitoneally with labeled tumor cells followed by rituximab, ofatumumab or PBS injection 16 hours later and finally assessed the number of tumor cells washed out from peritoneal cavity after another 24 hours. When inoculated with a low initial number of EL4-CD20 cells, fewer cells were recovered from wild-type and FcR -/animals treated with rituximab or ofatumumab compared to PBS -treated mice. However, application of anti-CD20 mAb was ineffective in FcRdeficient mice when ten times more tumor cells were applied. Notably, to combat such high numbers of tumor cells both functional complement and FcR receptors were necessary. Imai and colleagues used EL4 cells but a different target (gangliozyde GD2) and showed that complement may be irrelevant or has supplementary role in therapeutic effect depending on the concentration of sensitizing antibody 70 . Taken together, different lymphoma cells and their number together with different mouse strains and different anti-CD20 antibodies may generate too many variables making a unanimous conclusion impossible to draw. Instead, the picture from animal studies seems to be model-dependent and thus conclusions are resistant to generalization.
Conclusions from observations in man.
In spite of translational problems described above, animal studies may give us a hint of what can happen when CD20 mAbs are used in humans. However, in vitro and ex vivo studies performed on cells isolated from patients and their subsequent correlation with clinical parameters seem to be more adherent to the real, clinical situation.
Nonetheless, these approaches have their own limitations. Some methods used to measure the activity of immune cells or to indicate cell death may generate artefacts and these problems were recently described in review by Golay and Introna 71 . Also, the multifactorial nature of immune system-mediated killing mechanisms requires consideration of every single parameter as a variable influencing the total readout, before one merges data from different studies. Otherwise, as with the use of differing animal models, one may conclude that obtained results are contradictory. All cell types were equally sensitive to all killing mechanisms except for CDC, which was dependent on the combination of expression levels of CD20 and membrane bound complement inhibitors. Follicular lymphomas exhibited the most efficient lysis due to CDC while small lymphocytic lymphomas were the most resistant type, which followed the clinical data describing the response to rituximab 24, 73 . However, another study showed that lymphocytes isolated from lymph nodes of patients subsequently treated with rituximab did not significantly differ in expression of complement inhibitors or CDC susceptibility when patients were classified into responder, partial responder and nonresponder groups 74 . Authors also eliminated CD20 as a single parameter influencing the outcome, since there were no significant differences in its expression between the groups, but data were not related to the absolute number of CD20 per cell and one can speculate whether the expression was not already in the range of saturation of the sigmoidal curve described by van Meerten et al in their in vitro studies 41 . Trying to reconcile these results, it was suggested that supracellular factors (including tumor burden, which would be in agreement with mouse model experiments 69 ) are responsible for the overall effect and CDC could still play an important role as a part of the whole machinery, which fuels the other components 25 . Such a scenario appears reasonable if one considers the existence of a delayed response to mAb therapy in some patients 75 , which cannot originate from CDC due to its rapid kinetics. Initiation of the complement cascade leads to both CDC and CDCC and the latter may have been lost or underappreciated in all the experiments with relatively short time frame like minutes or a few hours 76 . For example, the beneficial effects of fresh-frozen plasma therapy administrated simultaneously to rituximab in CLL patients were proposed 77 and reported 78, 79 . Importantly, fresh-frozen plasma may serve as a source of all the components of complement, and thereafter they may be used in CDC or CDCC, and since none of the patients were deficient in certain type of immune cells or had any other kind of diagnosed immunodeficiency, one cannot exclude any of these two effector mechanisms. Nonetheless, CLL is characterized by a much lower level of CD20 expression compared to NHL 80 , and therefore any compensation or modulation of complement activity would certainly cause different outcomes. There are reports showing that some CLL patients either deficient or had altered expression of one or more complement components 81 Outwardly contradictory results are also presented regarding CLL and obinutuzumab, which is class II humanized IgG1 antibody, engineered in Fc portion 85 . Patz et al.
showed, that CDC is not involved in killing of isolated CLL cells 86 experiments were performed at different CD20 mAb concnetrations, 10 g/ml and 100 g/ml, respectively and also different cell number (4x 10 5 and 1x 10 6 cells/ml, respectively) thus making a direct comparison difficult. Another problem is the usage of DNA-binding dye 7-AAD as a marker of CDC in flow cytometry. Since it cannot pass intact cell membrane, negative result would mean no CDC but any positive result will inherit a risk of false positive readout due to e.g. secondary necrosis caused by dirext effect of mAb 88 . Interestingly, importance of tumor cell number in ADCC assays was confirmed by the fact that blocking of CD16 on NK cells significantly reduced obinutuzumab -mediated depletion of B cells in full blood from healthy individuals but not from CLL patients 86 . This phenomenon could be explained by different ratio of target to effector cells.
There is some evidence that individual polymorphisms in Fc receptors may be associated with clinical responses to rituximab as a single marker and these data favor ADCC as an important mechanism of therapeutic effect 89, 90 . However, when tumor cells taken before therapy from responders and non-responders from the same study were examined for in vitro sensitivity to ADCC, no significant differences were found between the groups. Thus, similarly to CDC, some important aspects may be underestimated in 
NK cells or leukocytes).
Work by Beurskens et al. 92 extends the hypothesis of tumor burden as a critical parameter for the effectiveness of killing mechanisms from mouse models 69 to human systems, while addressing ofatumumab, but also underlines the importance of optimal dosing of therapeutic antibody. Interestingly, increasing the dose of ofatumumab resulted in higher C3b deposition on CLL cells but did not increase CDC. Instead, complement became exhausted, and when the first wave of cells was treated with antibody concentrations exceeding the CDC saturation level, subsequently introduced CLL cells with ofatumumab could not be killed. Since elimination of CD20-positive cells from the bloodstream promotes the re-equilibration of these cells from other compartments, such experiments correspond to the in vivo situation, and reveal that tumor cell load, antibody concentrations and schedule of administration are important variables which should be taken into account when comparing experimental data.
Concluding remarks
There is still no conclusive evidence for the pivotal role of CDC, ADCC, apoptosis or non-apoptotic mechanisms as the predominant therapeutic effectors of various types of CD20 mAbs. Existing limitations concerning the translation of in vivo mouse experiments, together with technical issues of ex vivo assays, lead to as yet inconclusive answers. Heterogeneity among patients, tumor burden and treatment regimens add further to this problem. In spite of probable direct competition on the surface of single cell, the variuos mechanisms may cooperate in terms of whole populations of tumor cells. Identification of strong, single factors predicting the outcome of therapy would be valuable, but they must be assessed individually for the different narrowly classified lymphomas, as they differ in composition of membrane proteins or kinase activity, which influence vulnerability to mAb therapy and sensitivity to complement and the other effector functions. It seems that in most cases such a single predicting parameter has been extremely hard to identify because of too many variables crucial for therapy, or due to the generation of possible artefacts by assay methods. For that reason, one way to proceed is to identify tests, which will better discriminate between particular effector mechanisms, such as CDC and CDCC or CDC and direct apoptotic / non-apoptotic killing of tumor cells. Having a clear picture of which effector mechanism is crucial for a given lymphoma type and tumor cells with given parameters, one could attempt to further modulate the existing anti-CD20 immunotherapeutics in order to maximize the favorable killing system at the possible expense of others which may be less important. Following the clinical approval of rituximab and ofatumumab, next generation CD20 mAbs have been introduced in clinical trials, and there are also attempts to introduce additional modifications resulting in multifunctional activities 93, 94 .
Understanding the relative contribution of particular effector mechanisms are very likely to contribute to further clinical improvement of these therapeutics.
Conflict of interest statement
AÖ has received honoraria for lectures and advisory boards by Glaxo-Smith Kline and Sanofi. Table 1 . Anti-CD20 antibodies in clinical trials and clinically approved. Data were compiled from references 43, 44, 29, 35, 45 and updated from www.clinicaltrials.gov # -bound to I 131 , § -bound to Y 90 , n.s.not specified Alternatively, C3b binds to the cell surface, where it forms a novel platform for alternative C3/C5 convertases (C3bBb or C3bBbC3b) acting as an amplification loop of the classical complement pathway. The cleavage product of C5, C5b, is inserted into the cell membrane and initiates the assembly of MAC together with C6, C7, C8 and several C9 molecules, leading to osmotic cell lysis. ADCC (2) needs a moderate, number of CD20-mAb complexes compared to CDC, but seems to act in a competitive manner with CDC. The first step is the recognition of the antibody Fc portion by Fc receptors on effector cells (mainly NK cells but also neutrophils or eosinophils). Then, effector cells release the content of specific granules containing pore-forming and cytotoxic compounds, which target the B cell and lead to its programmed or spontaneous cell death.
Acknowledgments

Figure legend
Direct effects (3) cause cell death without additional effector cells or serum proteins but by binding of CD20 by mAbs alone. Aggregation of B cells by anti-CD20 Abs may precede caspase -independent cell death, as described for tositumomab 36 , reactive oxygen species -dependent cell death (described recently for obinutuzumab 37 ) or apoptotic cell death 95, 96 .
